Bainomugisa CK, Dasgupta P, Cameron JK, Tran B, Cramb SM, Baade PD. Spatial patterns of testicular cancer diagnosis in Australia, 2010-2019. Spatial and Spatio-temporal Epidemiology. 2025;55:10.1016/j.sste.2025.100745
Shahnam A, Hitchen N, Manoharan S, John T, Mileshkin L, Solomon B, Sandhu S, Luen SJ, Desai J, Tran B. Impact of age and comorbidity on safety outcomes in phase 1 trial participants for metastatic solid malignancies. Journal of Geriatric Oncology. 2025;16(8):10.1016/j.jgo.2025.102721
Hiong A, Lynam J, Weickhardt A, Wong S, Sengupta S, Manohar P, Wong L, Dundee P, Lawrentschuk N, Zhang AY, Anton A, Raghunath A, Gibbs P, Tran B. Perioperative chemotherapy use and related outcomes in muscle‐invasive bladder cancer in Australia. BJUI Compass. 2025;6(9):10.1002/bco2.70083
Aziz NA, Ng K, Alifrangis C, Tran B, Conduit C, Liow E, Ackerman C, Georgescu R, Jamal T, Relton C, Mayer E, Nicol D, Cazzaniga W, Huddart R, Reid A, Shamash J, Rajan P. Therapy de‐escalation for testicular cancer (THERATEST): A multi‐centre observational cohort feasibility study of de‐escalation therapies for good prognosis stage II germ cell tumours. BJUI Compass. 2025;6(8):10.1002/bco2.70057
Furic L, Ferreira R, Hannan K, Kusnadi E, Panov K, George A, Huglo A, Lawrence M, Tran B, Desai J, Drygin D, Haddach M, Hein N, Hannan RD. 77P PMR-116, a second generation ribosome biogenesis inhibitor, displays antitumour activity in a wide range of preclinical cancer models and on-target activity in a phase I trial. ESMO Open. 2025;10:10.1016/j.esmoop.2025.105427
Manoharan S, Shahnam A, Hitchen N, Williams S, Zhong Y, Shaya SJ, Mweempwa A, Mileshkin L, Solomon B, Luen SJ, Desai J, Tran B. 115O PROPOSE: Predicting phase I trial fitness using patient-reported outcomes and a clinician-completed prognostic index. ESMO Open. 2025;10:10.1016/j.esmoop.2025.105468
Manoharan S, Shahnam A, Hitchen N, John T, Mileshkin L, Solomon B, Sandhu SK, Luen SJ, Desai J, Tran B. 118P Impact of age and comorbidity on safety outcomes in phase I trials participants for metastatic solid malignancies. ESMO Open. 2025;10:10.1016/j.esmoop.2025.105471
Moody SC, Fietz D, Nathaniel B, Frydenberg M, Tran B, Schuppe H, Loveland KL. Spatial transcriptomics mapping of immune cell and TGFβ signalling pathway heterogeneity in testicular germ cell tumours. Andrology. 2025;:10.1111/andr.70100
Conduit C, Bagrodia A, Hamilton RJ, Feldman DR, Tran B. Optimal Management of Stage II Seminoma: Preventing Harm While Preserving Cure.JCO Oncology Practice. 2025;:10.1200/op-25-00252
Williams C, Inderjeeth A-J, Hong W, McKenzie J, Anton A, Weickhardt A, Wong S, Shapiro J, Parente P, Goh J, Torres J, Smith A, Joshua A, Brown S, Steer C, Johns J, Gibbs P, Tran B, Azad AA. Treatment patterns and outcomes for younger patients with metastatic castration-resistant prostate cancer (mCRPC); An Australian prospective registry study. Clinical Genitourinary Cancer. 2025;23(3):10.1016/j.clgc.2025.102345
